

**PEPPERPRINT**

A NEW DIVERSITY




# Autoantibody signatures in SARS-CoV-2 infected and vaccinated individuals

Dr. Kirsten Heiss  
Research & Development  
PEPperPRINT GmbH

November 2021


# Coronavirus disease 2019 (COVID-19)



Source: Talotta R. *et al.*, *World J Clin Cases*, 2020 Sep 6;8(17):3621-3644

- Respiratory illness caused by SARS-CoV-2
- Course of disease varies in symptoms and severity
- Immune system presents as double-edged sword  
*Viral clearance or excessive inflammation and autoimmunity*
- Several immune-mediated disorders have been described in SARS-CoV-2-infected individuals
- Presence of autoantibodies in COVID-19 patients

# Mechanisms for viral-induced autoimmunity



Source: Moody R. *et al.*, *Int J Mol Sci*, 2021 Aug 20;22(16)

- **Molecular mimicry:**

Immune responses towards epitopes that are shared between virus and human proteins

- **Bystander activation**

Autoreactive immune cell activation due to the release of self antigens


A list of autoimmune diseases and autoantibodies associated with COVID-19 infection.

Autoimmune disease/syndromes secondary to COVID-19 infection	Circulating autoantibodies reported in COVID-19 patients
Guillain-Barré syndrome	Anti-nuclear antibodies (ANA)
Miler Fisher Syndrome (MFS)	Anti-cardiolipin (aCL) antibodies
Antiphospholipid syndrome	Anti-β2 glycoprotein 1 (aβ2GP1) antibodies
Immune thrombocytopaenic purpura	Anti-MDA5 antibodies
systemic lupus erythematosus (SLE)	Anti RBC antibodies (direct anti globulin)
Kawasaki disease	LAC –lupus anticoagulant
Cold agglutinin disease & autoimmune hemolytic anemia	Antiprothrombin IgM
Neuromyelitis optica	Antiphosphatidylserine IgM/IgG
NMDA-receptor encephalitis	Antiannexin V IgM/IgG
Myasthenia gravis	Anti-GD1b antibodies
Type I diabetes	Anti-heparin PF4 complex antibody
Large vessel vasculitis & thrombosis	pANCA AND cANCA
Psoriasis	Anti-CCP antibodies
Subacute thyroiditis	
Graves' disease	
Sarcoidosis	
Inflammatory arthritis	

Source: Halpert G. and Shoenfeld Y., *Autoimmun Rev.*, 2020


- Various autoantibodies were found in COVID-19 patients
- (Possible) association with life-threatening SARS-CoV-2 infection / poor prognosis for some of the autoantibodies
- For others, clinical significance is unclear so far
- Potentially there are more autoantibody reactivities existing which are unknown so far

# Screening for epitope-specific antibody responses




# Our Platform Technology

- High spot density (1,200 peptides/cm<sup>2</sup>)
- Digital printing flexibility: multiple formats with high scalability
- Fast production times
- High peptide quality by routine double coupling
- Very low material consumption









Study 1: Screening of COVID-19 patient sera with different disease outcomes against human autoimmune disease-associated linear epitopes




# Study outline


Study 2: Investigating antibody responses against epitopes shared between SARS-CoV-2 & human proteins in infected subjects **and** pre- and post-COVID-19 vaccination



# Autoantibody signatures in COVID-19 patients




Epitope-resolved view of autoantibody responses



# Autoantibody signatures in COVID-19 patients






# Epitope signatures in severe COVID-19





# Antibody responses against shared epitopes

Naive cohort  
(COVID-19 negative)      Mild COVID-19  
(COVID-19 cohort 1)      Severe COVID-19  
(COVID-19 cohort 2)



Lucchese et al., 2020; Gamazza et al., 2020;  
Kanduc et al., 2020; Ehrenfeld et al., 2020


# Proteome-wide anti-SARS-CoV-2 antibody responses



SARS-CoV-2 naive






SARS-CoV-2 positive







# Antibody responses against shared epitopes




# Antibody responses against shared epitopes


IgG reactivity to epitopes shared between SARS-CoV-2 & human proteins in SARS-CoV-2-infected individuals




# Antibody responses against shared epitopes



# Antibody responses against shared epitopes



# Antibody responses against shared epitopes







## DEDDSEPV:

- conserved B cell epitope in SARS-CoV and SARS-CoV-2 Spikes
- also found in a T cell epitope of SARS-CoV-2 Spike
- bind to various HLA's including those associated with autoimmune disease

(Fath MK *et al.*, 2021)




# Vaccination-induced antibody responses

Pre-vaccinated vs. Post-vaccinated




# Vaccination-induced antibody responses

Pre-vaccinated vs. Post-vaccinated






# Vaccination-induced antibody responses

IgG responses




# Antibody responses against shared epitopes

Pre-vaccinated vs. Post-vaccinated





Vaccination  
pre post



# Antibody responses against shared epitopes


IgG reactivity to epitopes shared between SARS-CoV-2 Spike & human proteins in COVID-19-vaccinated individuals



SARS-CoV-2 Antigen	Human protein with homologous sequence	Peptide sequence
Spike	Maestro heat-like repeat-containing protein family member 9	LPPLLD
Spike	EMILIN-3	KVEAEVQ
Spike	Unconventional myosin-XVI	DEDDSEPV

# Antibody responses against shared epitopes

IgG reactivity to epitopes shared between SARS-CoV-2 Spike & human proteins



➤ More frequent cross-reactivity in infected than in vaccinated subjects

## **Epitope-specific autoantibody screening in COVID-19 patients with different disease outcomes revealed:**

- Heterogeneous epitope reactivity patterns between study groups with far stronger autoantibody responses in severely ill subjects
- Severe COVID-19: numerous IgG and/or IgA-specific autoantibody reactivities
- Several epitopes can be assigned to nuclear autoantigens, others may be summarized as tissue-associated autoantigens
- Studies with larger cohorts are needed to confirm identified epitopes (and clinical relevance)

## **Antibody responses recognizing linear epitopes shared between SARS-CoV-2 & human proteins revealed:**

- SARS-CoV-2 infected subjects: few antibody responses to the selected 6-14mer peptides shared between SARS-CoV-2 and human proteins were detected
- No antibody responses against most of the selected 6-14mer peptides shared between SARS-CoV-2 Spike and human proteins detected after COVID-19 vaccination
- Infection versus vaccination: cross-reactive antibodies against peptides shared between SARS-CoV-2 Spike and human proteins were detected more frequently after infection
- Whether or not antibodies recognizing DEDDSEPV have a clinical relevance remains to be determined

PEPPERPRINT  
A NEW DIVERSITY



# Thank you for joining the webinar

## Contact

Dr. Kirsten Heiss

Research & Development

PEPperPRINT GmbH

Tullastrasse 2

69126 Heidelberg, Germany

Visit us: [www.pepperprint.com](http://www.pepperprint.com)

Get in touch: [info@pepperprint.com](mailto:info@pepperprint.com)

 [pepperprint-gmbh](https://www.linkedin.com/company/pepperprint-gmbh)

 [@pepperchip](https://twitter.com/pepperchip)

 [pepperprint.gmbh](https://www.facebook.com/pepperprint.gmbh)